Sign up to save your podcasts
Or
Share Helix BioPharma Appoints Dr. Thomas Mehrling as CEO to Drive Clinical Development Plan
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Helix BioPharma Appoints Dr. Thomas Mehrling as CEO to Drive Clinical Development Plan
Helix BioPharma has named Dr. Thomas Mehrling as its new CEO, bringing his extensive experience in pharmaceutical oncology to lead the company's clinical development plan. Dr. Mehrling will focus on achieving the company's clinical milestones, starting with a Phase II study for non-small cell lung cancer. Helix's chairman expressed confidence in Dr. Mehrling's leadership and commitment to innovation in cancer treatment.
View all episodes
By NewsRampHelix BioPharma has named Dr. Thomas Mehrling as its new CEO, bringing his extensive experience in pharmaceutical oncology to lead the company's clinical development plan. Dr. Mehrling will focus on achieving the company's clinical milestones, starting with a Phase II study for non-small cell lung cancer. Helix's chairman expressed confidence in Dr. Mehrling's leadership and commitment to innovation in cancer treatment.